R&D costs and returns by therapeutic category

Drug Information Journal

Volumn 38, Issue 3, 2004, Pages 211-223

  DiMasi, Joseph A ^a   Grabowski, Henry G ^b   Vernon, John ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Drug development costs; R D; Therapeutic class

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC SEDATIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG SCREENING; PRIORITY JOURNAL; UNITED STATES;

EID: 4344623391     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150403800301     Document Type: Article

References (11)

1. DiMasi JA, Hansen RW, Grabowski HG, et al. Cost of innovation in the pharmaceutical industry. J Health Econ. 1991;10:107-142.
2. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-195.
3. Grabowski HG, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. PharmacoEconomics. 2002;20 Suppl. 3:11-29.
4. Pollack A. Despite billions for discoveries, pipeline of drugs is far from full. The New York Times, April 19, 2002.
5. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. PharmacoEconomics. 2002;20 Suppl. 3:1-10.
6. DiMasi JA, Hansen RW, Grabowski HG, et al. Research and development costs for new drugs by therapeutic category: a study of the US pharmaceutical industry. PharmacoEconomics. 1995;7(2):152-169.
7. DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther. 2001;69:297-307.
8. Annual report: the Med Ad News 500: the world's best selling medicines. Med Ad News. 2001;20(5).
9. IMS Health Incorporated. IMS Drug Monitor. World Drug Purchases-Retail Pharmacies. Fairfield, CT: IMS Health Incorporated; 2003.
10. Scrip's 2002 Yearbook. 18th Edition-Volume 2. Richmond, Surrey, UK: PJB Publications Ltd. 2002:278.
11. Scherer FM. The link between gross profitability and pharmaceutical R&D spending. Health Aff. 2001;20(5):136-140.